Mirae Asset Global Investments Co. Ltd. Increases Stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Mirae Asset Global Investments Co. Ltd. grew its stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 1,173.3% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 87,539 shares of the company’s stock after purchasing an additional 80,664 shares during the period. Mirae Asset Global Investments Co. Ltd.’s holdings in Recursion Pharmaceuticals were worth $611,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Allspring Global Investments Holdings LLC purchased a new stake in Recursion Pharmaceuticals during the third quarter worth $25,000. GAMMA Investing LLC boosted its stake in shares of Recursion Pharmaceuticals by 1,588.4% during the 2nd quarter. GAMMA Investing LLC now owns 6,416 shares of the company’s stock worth $48,000 after acquiring an additional 6,036 shares in the last quarter. Amalgamated Bank grew its position in shares of Recursion Pharmaceuticals by 52.4% during the 2nd quarter. Amalgamated Bank now owns 7,152 shares of the company’s stock valued at $54,000 after acquiring an additional 2,459 shares during the period. San Luis Wealth Advisors LLC purchased a new position in shares of Recursion Pharmaceuticals in the 3rd quarter valued at about $69,000. Finally, Vontobel Holding Ltd. acquired a new position in Recursion Pharmaceuticals in the 3rd quarter worth about $70,000. Institutional investors and hedge funds own 89.06% of the company’s stock.

Recursion Pharmaceuticals Price Performance

Recursion Pharmaceuticals stock opened at $6.40 on Friday. The company has a fifty day simple moving average of $6.63 and a 200-day simple moving average of $7.64. The firm has a market capitalization of $1.80 billion, a price-to-earnings ratio of -3.95 and a beta of 0.81. The company has a quick ratio of 6.07, a current ratio of 6.07 and a debt-to-equity ratio of 0.04. Recursion Pharmaceuticals, Inc. has a 52-week low of $5.03 and a 52-week high of $15.74.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.05). The business had revenue of $14.42 million during the quarter, compared to analyst estimates of $11.96 million. Recursion Pharmaceuticals had a negative net margin of 755.37% and a negative return on equity of 79.47%. The firm’s revenue was up 30.9% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.38) EPS. On average, equities analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.58 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

RXRX has been the subject of a number of recent analyst reports. KeyCorp cut their price objective on Recursion Pharmaceuticals from $16.00 to $12.00 and set an “overweight” rating for the company in a research report on Thursday, July 11th. Jefferies Financial Group reduced their price objective on shares of Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating for the company in a research report on Tuesday, September 3rd. Leerink Partners decreased their price objective on shares of Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating on the stock in a report on Tuesday, September 3rd. Finally, Needham & Company LLC reduced their price target on shares of Recursion Pharmaceuticals from $16.00 to $11.00 and set a “buy” rating for the company in a research report on Wednesday, September 4th. Four research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $9.40.

Insider Buying and Selling

In other Recursion Pharmaceuticals news, CEO Christopher Gibson sold 30,000 shares of the company’s stock in a transaction on Wednesday, August 7th. The stock was sold at an average price of $7.10, for a total value of $213,000.00. Following the completion of the sale, the chief executive officer now directly owns 758,738 shares in the company, valued at $5,387,039.80. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other Recursion Pharmaceuticals news, CEO Christopher Gibson sold 30,000 shares of Recursion Pharmaceuticals stock in a transaction dated Wednesday, August 7th. The shares were sold at an average price of $7.10, for a total transaction of $213,000.00. Following the transaction, the chief executive officer now directly owns 758,738 shares of the company’s stock, valued at $5,387,039.80. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Tina Marriott sold 6,000 shares of the business’s stock in a transaction dated Thursday, August 29th. The shares were sold at an average price of $7.56, for a total transaction of $45,360.00. Following the completion of the transaction, the chief operating officer now owns 521,138 shares in the company, valued at $3,939,803.28. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 213,129 shares of company stock worth $1,398,937. 15.75% of the stock is owned by corporate insiders.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.